Skip to main content

Bristol Myers-Squibb, Saladax Expand Companion Dx Deal to Include Ortho-Clinical Diagnostics

NEW YORK (GenomeWeb News) – Bristol Myers-Squibb and Saladax Biomedical today expanded an agreement covering companion diagnostics to include Johnson & Johnson's Ortho-Clinical Diagnostics.

The three firms will collaborate to develop and gain regulatory approval of certain diagnostic assays. Saladax and Ortho-Clinical have a separate agreement to commercialize assays resulting from the deal.

Financial and other terms of both deals were not disclosed.

Saladax and Bristol-Myers Squibb originally reached a partnership in May 2010 to develop clinical diagnostic tests for certain drug compounds in Bristol Myers-Squibb's pipeline. The terms of that deal called for the two firms to collaborate on development and regulatory approvals.

Saladax had exclusive global rights to commercialize assays developed from the collaboration.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.